E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036376 |
E.1.2 | Term | Post herpetic neuralgia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1.To evaluate the analgesic efficacy of varenicline versus placebo in patients with postherpetic neuralgia (PHN)
2.To evaluate the safety and tolerability of varenicline versus placebo in patients with postherpetic neuralgia.
3.To characterize the pharmacokinetics of varenicline in patients with post-herpetic neuralgia. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
1. Male or female, at least 18 years of age.
Females – Non-childbearing Potential: Female subjects of non-childbearing potential must meet at least one of the following criteria: • Post menopausal females • Females who are surgically sterile, defined as having had a documented hysterectomy and/or bilateral oophorectomy
Females – Childbearing Potential: • Defined as using adequate contraception consisting of 2 forms of birth control, one of which must be a barrier method, is not pregnant, lactating, and is not breastfeeding. Females of childbearing potential must have a negative serum pregnancy test at Baseline (V1).
Male Contraception Guidelines: • Male patients must agree that female spouses/partners will use contraception as defined above or be of non-childbearing potential (post-menopausal or surgically sterile);
2. Patients must have pain present for more than 3 months after healing of the Herpes zoster skin rash. There is no upper limit on the duration of PHN;
3. Patients must have a score of greater than or equal to (≥) 4 for pain from PHN on the 11- point NRS pain scale administered in the clinic at the Baseline (V1) visit. Note that the baseline phase of the study will only begin after the required 2-week minimum washout period from all prohibited concomitant medications;
4. Patients must have an average daily pain score greater than or equal to (≥) 4 and completed at least 4 daily pain diaries over the 7 days of the Baseline phase of the study (assessed at V2);
5. Patients must be able to understand and cooperate with trial procedures, and have signed a written informed consent prior to entering the trial.
|
|
E.4 | Principal exclusion criteria |
1.Patients who are tobacco users including cigarette smokers and users of non-cigarette tobacco products within 6 months prior to Baseline. Use of smoking cessation products including prescription medications such as buproprion and varenicline within 6 months prior to Baseline;
2.Patients who have undergone neurolytic or neurosurgical therapy including skin excisions for PHN;
3.Severe pain, which may impair the self-assessment of the pain due to PHN;
4.Skin conditions in the affected dermatome that could alter sensation, other than PHN;
5.Chronic hepatitis B or C, acute hepatitis B or C within the past 3 months;
6.History of HIV infection;
7.A history of alcohol or illicit drug abuse or dependency in the past 2 years. In addition, patients who fail a urine toxicology screen for illegal drugs;
8.Active cancer, including suspected metastases, or treatment for cancer or remission from any cancer other than cutaneous basal cell or squamous cell carcinoma resolved by excision for less than 5 years prior to Baseline;
9.History within the previous 6-months of: myocardial infarction, cardiac arrhythmia (e.g. atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, supraventricular tachycardia, (ventricular tachycardia, left ventricular failure), New York Heart Association (NYHA) Class III-IV congestive heart failure requiring treatment, unstable angina, coronary angioplasty, coronary artery bypass grafting (CABG) or cerebrovascular accident (including transient ischemic attacks);
10.Presenting with: • Any condition possibly affecting oral drug absorption (eg, gastrectomy or clinically significant diabetic gastroenteropathy); • Any clinically significant active infection;
11.A major surgical operation within 1 month of Baseline;
12.Uncontrolled hypertension or a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 95 mm Hg at Baseline;
13.Clinically significant abnormal 12-lead ECG at Baseline;
14.Evidence of organ dysfunction or hematopoietic disorder based on any of the following assessments: • AST or ALT >1.5 x ULN • Total bilirubin >1.5 x ULN • Estimated serum creatinine clearance < 30 mL/min
15.Use of any prohibited concomitant medications during the last 2 weeks of the Screening period prior to the start of Baseline
16.Use of any investigational drug agent or device during this study or within 1 month, or 5 half lives, prior to Baseline whichever is longer;
17.History of severe drug induced hypersensitivity (ie, anaphylaxis);
18.Patients with moderate or severe depression or anxiety based on investigator judgment or major depressive/anxiety disorder as defined by DSM-IV diagnostic criteria or depression/anxiety sub-scale score 11 on the Hospital Anxiety and Depression Scale at Baseline;
19.“Moderate” or “severe” scores on any of the items comprising the Behaviour Monitoring Aid at Baseline;
20.Patients with active suicidal ideation or suicidal behaviour (including suicide attempt) within 2 years prior to Baseline as determined through the use of the C-SSRS (Columbia-Suicide Severity Rating Scale) or by the investigator’s clinical judgment at the Baseline or Randomization / Day 1 visits;
21.History, diagnosis or signs and symptoms of clinically significant neurological disease, including, but not limited to: • Alzheimer’s disease or other types of dementia;
22.Inability to comprehend, or unwillingness to follow, the study requirements
23. Patients who do not agree to abstain from using tobacco products of any kind, smoking cessation products (eg, nicotine replacement therapy, buproprion) or marijuana during study participation;
24.Patients who plan to donate blood or blood products during participation or within 30 days after the end of the study;
25.A body mass index (BMI) less than 15 kg/m2 or greater than 39 kg/m2. No patient will be enrolled with a weight less than 100 pounds (45.5.kg);
26.Demonstrated intolerance or hypersensitivity to, the active substance or to any of the excipients contained in the marketed product;
27.A history of intolerance or hypersensitivity to acetaminophen (paracetamol) or any of its excipients or existence of a medical condition or use of any concomitant medication for which the use of acetaminophen (paracetamol) is contraindicated;
28.Other severe acute or chronic medical or psychiatric condition or clinical laboratory abnormality that may increase the risk associated with study participation, or investigational product administration, or may interfere with the interpretation of study results. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the change from Baseline period (defined as the period starting on V1 (Day -7) up to and including Day -1 (the day before Day 1/Randomization) to Week 4 in the average weekly pain score using the 11-point NRS (Numeric Rating Scale) daily diary. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 24 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 21 |